Cargando…

The Percentage of Free PSA and Urinary Markers Distinguish Prostate Cancer from Benign Hyperplasia and Contribute to a More Accurate Indication for Prostate Biopsy

The main advantage of urinary biomarkers is their noninvasive character and the ability to detect multifocal prostate cancer (CaP). We have previously implemented a quadruplex assay of urinary markers into clinical practice (PCA3, AMACR, TRPM8 and MSMB with KLK3 normalization). In this study, we aim...

Descripción completa

Detalles Bibliográficos
Autores principales: Huskova, Zlata, Knillova, Jana, Kolar, Zdenek, Vrbkova, Jana, Kral, Milan, Bouchal, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7344460/
https://www.ncbi.nlm.nih.gov/pubmed/32630458
http://dx.doi.org/10.3390/biomedicines8060173
_version_ 1783555948906807296
author Huskova, Zlata
Knillova, Jana
Kolar, Zdenek
Vrbkova, Jana
Kral, Milan
Bouchal, Jan
author_facet Huskova, Zlata
Knillova, Jana
Kolar, Zdenek
Vrbkova, Jana
Kral, Milan
Bouchal, Jan
author_sort Huskova, Zlata
collection PubMed
description The main advantage of urinary biomarkers is their noninvasive character and the ability to detect multifocal prostate cancer (CaP). We have previously implemented a quadruplex assay of urinary markers into clinical practice (PCA3, AMACR, TRPM8 and MSMB with KLK3 normalization). In this study, we aimed to validate it in a larger cohort with serum PSA 2.5–10 ng/mL and test other selected transcripts and clinical parameters, including the percentage of free prostate-specific antigen (PSA) (% free PSA) and inflammation. In the main cohort of 299 men, we tested the quadruplex transcripts. In a subset of 146 men, we analyzed additional transcripts (CD45, EPCAM, EZH2, Ki67, PA2G4, PSGR, RHOA and TBP). After a prostate massage, the urine was collected, RNA isolated from a cell sediment and qRT-PCR performed. Ct values of KLK3 (i.e., PSA) were strongly correlated with Ct values of other genes which play a role in CaP (i.e., PCA3, AMACR, TRPM8, MSMB and PSGR). AMACR, PCA3, TRPM8 and EZH2 mRNA expression, as well as % free PSA, were significantly different for BPH and CaP. The best combined model (% free PSA plus PCA3 and AMACR) achieved an AUC of 0.728 in the main cohort. In the subset of patients, the best AUC 0.753 was achieved for the combination of PCA3, % free PSA, EPCAM and PSGR. PCA3 mRNA was increased in patients with inflammation, however, this did not affect the stratification of patients indicated for prostate biopsy. In conclusion, the percentage of free PSA and urinary markers contribute to a more accurate indication for prostate biopsy.
format Online
Article
Text
id pubmed-7344460
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-73444602020-07-14 The Percentage of Free PSA and Urinary Markers Distinguish Prostate Cancer from Benign Hyperplasia and Contribute to a More Accurate Indication for Prostate Biopsy Huskova, Zlata Knillova, Jana Kolar, Zdenek Vrbkova, Jana Kral, Milan Bouchal, Jan Biomedicines Article The main advantage of urinary biomarkers is their noninvasive character and the ability to detect multifocal prostate cancer (CaP). We have previously implemented a quadruplex assay of urinary markers into clinical practice (PCA3, AMACR, TRPM8 and MSMB with KLK3 normalization). In this study, we aimed to validate it in a larger cohort with serum PSA 2.5–10 ng/mL and test other selected transcripts and clinical parameters, including the percentage of free prostate-specific antigen (PSA) (% free PSA) and inflammation. In the main cohort of 299 men, we tested the quadruplex transcripts. In a subset of 146 men, we analyzed additional transcripts (CD45, EPCAM, EZH2, Ki67, PA2G4, PSGR, RHOA and TBP). After a prostate massage, the urine was collected, RNA isolated from a cell sediment and qRT-PCR performed. Ct values of KLK3 (i.e., PSA) were strongly correlated with Ct values of other genes which play a role in CaP (i.e., PCA3, AMACR, TRPM8, MSMB and PSGR). AMACR, PCA3, TRPM8 and EZH2 mRNA expression, as well as % free PSA, were significantly different for BPH and CaP. The best combined model (% free PSA plus PCA3 and AMACR) achieved an AUC of 0.728 in the main cohort. In the subset of patients, the best AUC 0.753 was achieved for the combination of PCA3, % free PSA, EPCAM and PSGR. PCA3 mRNA was increased in patients with inflammation, however, this did not affect the stratification of patients indicated for prostate biopsy. In conclusion, the percentage of free PSA and urinary markers contribute to a more accurate indication for prostate biopsy. MDPI 2020-06-25 /pmc/articles/PMC7344460/ /pubmed/32630458 http://dx.doi.org/10.3390/biomedicines8060173 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Huskova, Zlata
Knillova, Jana
Kolar, Zdenek
Vrbkova, Jana
Kral, Milan
Bouchal, Jan
The Percentage of Free PSA and Urinary Markers Distinguish Prostate Cancer from Benign Hyperplasia and Contribute to a More Accurate Indication for Prostate Biopsy
title The Percentage of Free PSA and Urinary Markers Distinguish Prostate Cancer from Benign Hyperplasia and Contribute to a More Accurate Indication for Prostate Biopsy
title_full The Percentage of Free PSA and Urinary Markers Distinguish Prostate Cancer from Benign Hyperplasia and Contribute to a More Accurate Indication for Prostate Biopsy
title_fullStr The Percentage of Free PSA and Urinary Markers Distinguish Prostate Cancer from Benign Hyperplasia and Contribute to a More Accurate Indication for Prostate Biopsy
title_full_unstemmed The Percentage of Free PSA and Urinary Markers Distinguish Prostate Cancer from Benign Hyperplasia and Contribute to a More Accurate Indication for Prostate Biopsy
title_short The Percentage of Free PSA and Urinary Markers Distinguish Prostate Cancer from Benign Hyperplasia and Contribute to a More Accurate Indication for Prostate Biopsy
title_sort percentage of free psa and urinary markers distinguish prostate cancer from benign hyperplasia and contribute to a more accurate indication for prostate biopsy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7344460/
https://www.ncbi.nlm.nih.gov/pubmed/32630458
http://dx.doi.org/10.3390/biomedicines8060173
work_keys_str_mv AT huskovazlata thepercentageoffreepsaandurinarymarkersdistinguishprostatecancerfrombenignhyperplasiaandcontributetoamoreaccurateindicationforprostatebiopsy
AT knillovajana thepercentageoffreepsaandurinarymarkersdistinguishprostatecancerfrombenignhyperplasiaandcontributetoamoreaccurateindicationforprostatebiopsy
AT kolarzdenek thepercentageoffreepsaandurinarymarkersdistinguishprostatecancerfrombenignhyperplasiaandcontributetoamoreaccurateindicationforprostatebiopsy
AT vrbkovajana thepercentageoffreepsaandurinarymarkersdistinguishprostatecancerfrombenignhyperplasiaandcontributetoamoreaccurateindicationforprostatebiopsy
AT kralmilan thepercentageoffreepsaandurinarymarkersdistinguishprostatecancerfrombenignhyperplasiaandcontributetoamoreaccurateindicationforprostatebiopsy
AT bouchaljan thepercentageoffreepsaandurinarymarkersdistinguishprostatecancerfrombenignhyperplasiaandcontributetoamoreaccurateindicationforprostatebiopsy
AT huskovazlata percentageoffreepsaandurinarymarkersdistinguishprostatecancerfrombenignhyperplasiaandcontributetoamoreaccurateindicationforprostatebiopsy
AT knillovajana percentageoffreepsaandurinarymarkersdistinguishprostatecancerfrombenignhyperplasiaandcontributetoamoreaccurateindicationforprostatebiopsy
AT kolarzdenek percentageoffreepsaandurinarymarkersdistinguishprostatecancerfrombenignhyperplasiaandcontributetoamoreaccurateindicationforprostatebiopsy
AT vrbkovajana percentageoffreepsaandurinarymarkersdistinguishprostatecancerfrombenignhyperplasiaandcontributetoamoreaccurateindicationforprostatebiopsy
AT kralmilan percentageoffreepsaandurinarymarkersdistinguishprostatecancerfrombenignhyperplasiaandcontributetoamoreaccurateindicationforprostatebiopsy
AT bouchaljan percentageoffreepsaandurinarymarkersdistinguishprostatecancerfrombenignhyperplasiaandcontributetoamoreaccurateindicationforprostatebiopsy